US EditionPublished • loading... • Updated
Trump administration announces 15 new drugs for Medicare price negotiation program
The third round of Medicare negotiations includes 15 drugs, marking the first inclusion of physician-administered medications, affecting 1.8 million enrollees, CMS said.
- The Trump administration announced 15 new drugs for Medicare price negotiation, including popular drugs like Trulicity and Biktarvy.
- The government previously negotiated prices for 25 prescription drugs, and this marks the third round of the program, totaling 40 drugs with lower prices.
- Six of the 15 new drugs are administered in doctor offices, while others are self-administered and covered by Part D.
Insights by Ground AI
55 Articles
55 Articles
Associated Press News+49 Reposted by 49 other sources
Trump administration announces 15 new drugs for Medicare price negotiation program
The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers.
·United States
Read Full Article
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Regional Media News
Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly, Pfizer and AbbVie for the third cycle of the Medicare Drug Price Negotiation Program, including the first products reimbursed under Medicare Part B. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Alan Barona) Brought to you by www.srnnews.com
Coverage Details
Total News Sources55
Leaning Left9Leaning Right5Center34Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 19%
C 71%
Factuality
To view factuality data please Upgrade to Premium
